Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)

• Company Description    MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland. Number of Employees: 114

• Price / Volume Information    Yesterday's Closing Price: $1.45 Daily Weekly Monthly 20 Day Moving Average: 810,531 shares Shares Outstanding: 106.61 (millions) Market Capitalization: $154.58 (millions) Beta: 1.20 52 Week High: $5.20 52 Week Low: $1.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.84% 1.03% 12 Week -31.28% -37.58% Year To Date -65.14% -68.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9713 KEY WEST AVENUE SUITE 400 - ROCKVILLE,MD 20850 USA ph: 301-944-1700 fax: 301-944-1703 ir@maxcyte.com http://www.maxcyte.com

• General Corporate Information    Officers Maher Masoud - President; Chief Executive Officer and Director Richard Douglas - Chairman Douglas Swirsky - Chief Financial Officer Yasir Al-Wakeel - Director Patrick J. Balthrop - Director Peer Information MaxCyte, Inc. (CORR.) MaxCyte, Inc. (RSPI) MaxCyte, Inc. (CGXP) MaxCyte, Inc. (BGEN) MaxCyte, Inc. (GTBP) MaxCyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 57777K106 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 106.61 Most Recent Split Date: (:1) Beta: 1.20 Market Capitalization: $154.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: 4.32 EPS Growth vs. Year Ago Period: -33.33% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: -18.43% vs. Previous Quarter: -18.12% ROE 06/30/25 - -22.12 03/31/25 - -19.90 12/31/24 - -18.94 ROA 06/30/25 - -19.10 03/31/25 - -17.24 12/31/24 - -16.46 Current Ratio 06/30/25 - 12.40 03/31/25 - 12.23 12/31/24 - 10.88 Quick Ratio 06/30/25 - 11.71 03/31/25 - 11.58 12/31/24 - 10.32 Operating Margin 06/30/25 - -125.22 03/31/25 - -110.92 12/31/24 - -106.28 Net Margin 06/30/25 - -125.22 03/31/25 - -110.92 12/31/24 - -106.28 Pre-Tax Margin 06/30/25 - -125.22 03/31/25 - -110.92 12/31/24 - -106.29 Book Value 06/30/25 - 1.79 03/31/25 - 1.88 12/31/24 - 1.95 Inventory Turnover 06/30/25 - 0.81 03/31/25 - 0.74 12/31/24 - 0.67 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©